The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
Alternative phosphate binders, such as CaCO3, have been shown to be effective in the control of phosphate (P) retention in hemodialysis patients (HDP). Additionally, both oral (POC) and iv (IVC) calcitriol are purported to be of benefit in the control of secondary hyperparathyroidism. This investigation was undertaken to determine: (1) the effectiveness of CaCO3 as the sole P binder in combination with low (2.5 mEq/L) Ca dialysate; (2) the effects of discontinuing Al(OH)3 binders on both unstimulated and stimulated Al concentrations; and (3) the comparative parathyroid hormone (PTH) response to both POC and IVC in a large group of hemodialysis patients. One hundred ninety-four HDP completed part 1 of the study where CaCO3 was substituted for Al(OH)3 as the sole P binder for 6 months. A cohort of 49 HDP was given desferoximine (40 mg/kg) initially and 10 months after using CaCO3. In part 2, 54 HDP were given POC and 97 HDP were given IVC in dosages of 0.25 to 0.5 micrograms/day and 1.5 to 6.0 micrograms/wk, respectively, for an additional 6 months. In part 1, Ca and P were not different from baseline values observed with Al(OH)3 therapy. Ionized Ca increased (P < 0.05) and PTH decreased (P < 0.001) during CaCO3 therapy without vitamin D. In part 2, PTH declined 23% with IVC and was unchanged with POC in equivalent dosages (P < 0.05) at 3 months. By 6 months, PTH declined a total of 54% with IVC and was unchanged with POC. Ca, ionized Ca, P, and serum calcitriol were greater (P < 0.05) in the IVC group at 6 months. Serum Al concentrations for the entire 194 HDP fell 65% (P < 0.0001) over 12 months. In the 49 HDP cohort, serum Al fell 43.6% (P < 0.001) and stimulated Al concentrations decreased 68.7% (P < 0.0001) after 10 months. We conclude that: (1) CaCO3 is as effective as Al(OH)3 in controlling P, (2) a small decrease in PTH is observed with CaCO3 alone, (3) serologic evidence of Al excess is virtually eliminated, (4) PTH suppression with IVC is superior to that seen with POC in equivalent doses.
Oettinger
C W
CW
Emory University School of Medicine, Atlanta, GA.
Oliver
J C
JC
Macon
E J
EJ
D000469:Alkaline Phosphatase / Q000097:blood; D002117:Calcitriol / Q000097:blood / Q000627:therapeutic use*; D002118:Calcium / Q000008:administration & dosage* / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000494:pharmacology*; D015312:Hemodialysis Solutions / Q000494:pharmacology*; D006801:Humans; D006934:Hypercalcemia / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D016105:Parathyroidectomy; D010710:Phosphates / Q000097:blood*; D011184:Postoperative Period; D006435:Renal Dialysis / Q000009:adverse effects
D015312:Hemodialysis Solutions; D010710:Phosphates; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002119:Calcium Carbonate; D002118:Calcium